1
|
Srivastava G, Mukherjee E, Mittal R, Ganjewala D. Geraniol and citral: recent developments in their anticancer credentials opening new vistas in complementary cancer therapy. Z NATURFORSCH C 2024; 79:163-177. [PMID: 38635829 DOI: 10.1515/znc-2023-0150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2023] [Accepted: 04/03/2024] [Indexed: 04/20/2024]
Abstract
About 10 million people are diagnosed with cancer each year. Globally, it is the second leading cause of death after heart disease, and by 2035, the death toll could reach 14.6 million. Several drugs and treatments are available to treat cancer, but survival rates remain low. Many studies in recent years have shown that plant-derived monoterpenes, particularly geraniol and citral, are effective against various cancers, including breast, liver, melanoma, endometrial, colon, prostate, and skin cancers. This trend has opened new possibilities for the development of new therapeutics or adjuvants in the field of cancer therapy. These monoterpenes can improve the efficacy of chemotherapy by modulating many signaling molecules and pathways within tumors. Analysis of reports on the anticancer effects published in the past 5 years provided an overview of the most important results of these and related properties. Also, the molecular mechanisms by which they exert their anticancer effects in cell and animal studies have been explained. Therefore, this review aims to highlight the scope of geraniol and citral as complementary or alternative treatment options in cancer therapy.
Collapse
Affiliation(s)
- Gauri Srivastava
- Amity Institute of Biotechnology, 77282 Amity University , Sector-125, Noida 201303, Uttar Pradesh, India
| | - Esha Mukherjee
- Amity Institute of Biotechnology, 77282 Amity University , Sector-125, Noida 201303, Uttar Pradesh, India
| | - Ruchika Mittal
- Amity Institute of Biotechnology, 77282 Amity University , Sector-125, Noida 201303, Uttar Pradesh, India
| | - Deepak Ganjewala
- Amity Institute of Biotechnology, 77282 Amity University , Sector-125, Noida 201303, Uttar Pradesh, India
| |
Collapse
|
2
|
Gu K, Ouyang P, Hong Y, Dai Y, Tang T, He C, Shu G, Liang X, Tang H, Zhu L, Xu Z, Yin L. Geraniol inhibits biofilm formation of methicillin-resistant Staphylococcus aureus and increase the therapeutic effect of vancomycin in vivo. Front Microbiol 2022; 13:960728. [PMID: 36147840 PMCID: PMC9485828 DOI: 10.3389/fmicb.2022.960728] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 08/16/2022] [Indexed: 12/04/2022] Open
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is among the common drug resistant bacteria, which has gained worldwide attention due to its high drug resistance and infection rates. Biofilms produced by S. aureus are known to increase antibiotic resistance, making the treatment of S. aureus infections even more challenging. Hence, inhibition of biofilm formation has become an alternative strategy for controlling persistent infections. In this study, we evaluated the efficacy of geraniol as a treatment for MRSA biofilm infection. The results of crystal violet staining indicated that 256 μg/mL concentration of geraniol inhibited USA300 biofilm formation by 86.13% and removed mature biofilms by 49.87%. Geraniol exerted its anti-biofilm effect by influencing the major components of the MRSA biofilm structure. We found that geraniol inhibited the synthesis of major virulence factors, including staphyloxanthin and autolysins. The colony count revealed that geraniol inhibited staphyloxanthin and sensitized USA300 cells to hydrogen peroxide. Interestingly, geraniol not only reduced the release of extracellular nucleic acids (eDNA) but also inhibited cell autolysis. Real-time polymerase chain reaction data revealed the downregulation of genes involved in biofilm formation, which verified the results of the phenotypic analysis. Geraniol increased the effect of vancomycin in eliminating USA300 biofilms in a mouse infection model. Our findings revealed that geraniol effectively inhibits biofilm formation in vitro. Furthermore, in combination with vancomycin, geraniol can reduce the biofilm adhesion to the implant in mice. This suggests the potential of geraniol as an anti-MRSA biofilm drug and can provide a solution for the clinical treatment of biofilm infection.
Collapse
|
3
|
Silva GDSE, de Jesus Marques JN, Moreira Linhares EP, Bonora CM, Costa ÉT, Saraiva MF. Review of anticancer activity of monoterpenoids: Geraniol, nerol, geranial and neral. Chem Biol Interact 2022; 362:109994. [DOI: 10.1016/j.cbi.2022.109994] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Revised: 05/05/2022] [Accepted: 05/24/2022] [Indexed: 01/18/2023]
|
4
|
Huang J, Fan P, Liu M, Weng C, Fan G, Zhang T, Duan X, Wu Y, Tang L, Yang G, Liu Y. Famotidine promotes inflammation by triggering cell pyroptosis in gastric cancer cells. BMC Pharmacol Toxicol 2021; 22:62. [PMID: 34686215 PMCID: PMC8539739 DOI: 10.1186/s40360-021-00533-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Accepted: 10/15/2021] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Cell pyroptosis has been characterized by cell swelling and pro-inflammatory factors release to aggravate inflammatory reaction., such as interlukin-1 beta (IL-1β) and interlukin18 (IL-18). However, the function of famotidine, an antagonist of histamine H2-receptor antagonists, in cell pyroptosis remained unknown. METHODS Real-time quantitative PCR (qPCR), western blotting (WB), LDH release assay and enzyme linked immunosorbent assay (Elisa) combined with inhibitor were performed to analyze the effect of famotidine on cell pyroptosis-related gene expression. RESULTS In this study, we found that famotidine (300 μm) treatment led to a phenomenon of cell pyroptosis as confirmed by LDH assay. Further results showed that famotidine triggered cell pyroptosis in gastric cancer cells by activation of NLPR3 inflammasomes including ASC, Caspase-1 and NLRP, leading to enhanced IL-18, not IL-1β, mature and secretion. What's more, the results also showed GSDME, not GSDMD, was increased in response to famotidine stimulation in BGC823 and AGS cells. Mechanically, phosphorylation of ERK1/2 was drastically enhanced in present with famotidine treatment, while inhibition of ERK1/2 activity by U0126 could reverse the promotion of famotidine in IL-18 secretion. CONCLUSION These findings revealed a novel role of famotidine in cell pyroptosis in patients with gastric cancer, a comprehensive consideration is needed in treatment of gastric cancer.
Collapse
Affiliation(s)
- Jin Huang
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China
| | - Pingsheng Fan
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China
| | - Miao Liu
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China
| | - Chengtao Weng
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China
| | - Gaofei Fan
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China
| | - Tengyue Zhang
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China
| | - Xiaohong Duan
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China
| | - Yang Wu
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China
| | - Lili Tang
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China
| | - Guohong Yang
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China
| | - Yabei Liu
- Department of Medical Oncology, the First affiliated Hospital of University of Science and Technology of China(West), Heifei, Anhui, China.
| |
Collapse
|